<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919503</url>
  </required_header>
  <id_info>
    <org_study_id>2256.00</org_study_id>
    <secondary_id>NCI-2010-01277</secondary_id>
    <secondary_id>2256.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG2809001</secondary_id>
    <nct_id>NCT00919503</nct_id>
  </id_info>
  <brief_title>Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders</brief_title>
  <official_title>Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II clinical trial studies how well treosulfan and fludarabine phosphate with or&#xD;
      without low dose radiation before donor stem cell transplantation works in treating patients&#xD;
      with nonmalignant (noncancerous) diseases. Hematopoietic cell transplantation has been shown&#xD;
      to be curative for many patients with nonmalignant (noncancerous) diseases such as primary&#xD;
      immunodeficiency disorders, bone marrow failure syndromes, hemoglobinopathies, and inborn&#xD;
      errors of metabolism (metabolic disorders). Powerful chemotherapy drugs and/or radiation are&#xD;
      often used to condition the patient before infusion of the new healthy donor cells. The&#xD;
      purpose of the conditioning therapy is to destroy the patient's abnormal bone marrow which&#xD;
      doesn't work properly in order to make way for the new healthy donor cells which functions&#xD;
      normally. Although effective in curing the patient's disease, many hematopoietic cell&#xD;
      transplantation regimens use intensive chemotherapy and/or radiation which can be quite&#xD;
      toxic, have significant side effects, and can potentially be life-threatening. Investigators&#xD;
      are investigating whether a new conditioning regimen that uses less intensive drugs&#xD;
      (treosulfan and fludarabine phosphate) with or without low dose radiation results in new&#xD;
      blood-forming cells (engraftment) of the new donor cells without increased toxicities in&#xD;
      patients with nonmalignant (noncancerous) diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive treosulfan intravenously (IV) over 2 hours on days -6&#xD;
      to -4 and fludarabine phosphate IV over 1 hour on days -6 to -2. Patients receive&#xD;
      anti-thymocyte globulin IV over 4-6 hours on days -4 to -2. Patients undergoing umbilical&#xD;
      cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
&#xD;
      TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or&#xD;
      umbilical cord blood (UCB) from the donor on day 0. The use of either bone marrow, PBSC, or&#xD;
      umbilical cord blood will depend on the donor status.&#xD;
&#xD;
      IMMUNOSUPPRESSION: Patients receive a combination of immunosuppressive medications to try and&#xD;
      prevent graft-versus-host disease. There are 2 regimens depending on the donor.&#xD;
&#xD;
      Regimen A: Patients undergoing bone marrow or PBSC transplantation receive tacrolimus daily&#xD;
      from day -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also&#xD;
      receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
&#xD;
      Regimen B: Patients undergoing UCB transplantation receive cyclosporine on days -3 to 100&#xD;
      followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate&#xD;
      mofetil on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2009</start_date>
  <completion_date type="Actual">June 10, 2020</completion_date>
  <primary_completion_date type="Actual">June 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preliminary Efficacy</measure>
    <time_frame>1 year following transplant</time_frame>
    <description>Number of patients engrafted (&gt;5% donor CD3+ peripheral blood chimerisms) at 1 year following transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>1 year following transplant</time_frame>
    <description>Number of patients who experienced non-relapse mortality by 1 year following transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade II-IV Acute Graft-versus-host Disease</measure>
    <time_frame>Day 100 post transplant</time_frame>
    <description>Number of patients diagnosed with overall grade II-IV acute GVHD by Day 100 post transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With of Chronic Graft-versus-host Disease</measure>
    <time_frame>1 year following transplant</time_frame>
    <description>Number of patients diagnosed with chronic GVHD and requiring systemic immunosuppression within 1 year following transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism CD3 at 100 Days Post Transplant</measure>
    <time_frame>Day 100 post transplant</time_frame>
    <description>Number of patients with peripheral blood donor chimerism for CD3 less than 5%, 5-49%, 50-94% and greater than or equal to 95% at 100 days post transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Response at One Year Following Hematopoietic Cell Transplantation</measure>
    <time_frame>1 year following transplant</time_frame>
    <description>Number of patients with no evidence of disease at one year following transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution Following Hematopoietic Cell Transplantation</measure>
    <time_frame>1 year following transplant</time_frame>
    <description>Number of patients with immune reconstitution (defined by a normal range CD3) at 1 year post transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infections</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>Number of participants with clinically significant infections (bacterial, fungal, viral) requiring treatment within 100 days following transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year following transplant</time_frame>
    <description>Number of patients alive at 1 year following transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism CD33 at Day 100 Post Transplant</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>Number of patients with peripheral blood donor chimerism for CD33 less than 5%, 5-49%, 50-94% and greater than or equal to 95% at 100 days post transplant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Non-Neoplastic Hematologic and Lymphocytic Disorder</condition>
  <arm_group>
    <arm_group_label>Regimen A (PBSCT and BMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B (UBCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Infused IV</description>
    <arm_group_label>Regimen A (PBSCT and BMT)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A (PBSCT and BMT)</arm_group_label>
    <arm_group_label>Regimen B (UBCT)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Regimen B (UBCT)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A (PBSCT and BMT)</arm_group_label>
    <arm_group_label>Regimen B (UBCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Regimen A (PBSCT and BMT)</arm_group_label>
    <arm_group_label>Regimen B (UBCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A (PBSCT and BMT)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Regimen B (UBCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Infused IV</description>
    <arm_group_label>Regimen A (PBSCT and BMT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Regimen A (PBSCT and BMT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo total body irradiation</description>
    <arm_group_label>Regimen B (UBCT)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A (PBSCT and BMT)</arm_group_label>
    <arm_group_label>Regimen B (UBCT)</arm_group_label>
    <other_name>1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-</other_name>
    <other_name>Dihydroxybusulfan</other_name>
    <other_name>Ovastat</other_name>
    <other_name>Treosulphan</other_name>
    <other_name>Tresulfon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplantation</intervention_name>
    <description>Single or double unit umbilical cord blood transplant, infused IV</description>
    <arm_group_label>Regimen B (UBCT)</arm_group_label>
    <other_name>Cord Blood Transplantation</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a nonmalignant disease treatable by allogeneic HCT&#xD;
&#xD;
          -  Patients with a known nonmalignant disease that is not clearly defined will need to be&#xD;
             discussed with the protocol principal investigator (PI) (Dr. Lauri Burroughs) and&#xD;
             potentially the nonmalignant board to determine if they are eligible for HCT on this&#xD;
             study&#xD;
&#xD;
          -  DONOR: Human leukocyte antigens (HLA)-identical related donors or unrelated donors&#xD;
             matched for HLA-A, B, C, DRB1, and DQB1 or mismatched for a single allele at HLA-A, B,&#xD;
             C, DRB1 or a single DQB1 antigen or allele mismatch by high resolution&#xD;
             deoxyribonucleic acid (DNA) typing&#xD;
&#xD;
          -  DONOR: PBSC is the preferred cell source (when feasible) for fully matched donors;&#xD;
             PBSC may also be used for a mismatched donor following discussion with the PI; bone&#xD;
             marrow is allowed when PBSC is not feasible or as determined by the PI&#xD;
&#xD;
          -  DONOR: HLA-matched sibling bone marrow in combination with HLA-matched sibling&#xD;
             umbilical cord blood if the HLA-matched sibling umbilical cord blood was collected and&#xD;
             stored; the HLA-matched sibling bone marrow and cord blood would be matched for HLA-A,&#xD;
             B, C, DRB1, and DQB1&#xD;
&#xD;
          -  DONOR: Unrelated Umbilical Cord Blood: Unit selection is based on the cryopreserved&#xD;
             total nucleated cell (TNC) dose and matching at HLA-A, B antigen level and DRB1 allele&#xD;
             level typing; while HLA-C antigen/allele level typing is not considered in the&#xD;
             matching criteria, if available, may be used to optimize unit selection&#xD;
&#xD;
          -  DONOR: Unrelated Umbilical Cord Blood: The patient and the cord blood unit(s) must be&#xD;
             matched for at least 4 of 6 loci as defined above&#xD;
&#xD;
          -  DONOR: Unrelated Umbilical Cord Blood: Selection of two umbilical cord blood (UCB)&#xD;
             units is allowed to provide sufficient cell dose&#xD;
&#xD;
          -  DONOR: Unrelated Umbilical Cord Blood: The UCB unit with the least HLA disparity (with&#xD;
             the patient) will be selected first (i.e., selection priority is 6/6 match &gt; 5/6&#xD;
             match&gt; 4/6 match); additional UCB units then may be selected to achieve the required&#xD;
             cell dose; if a second unit is required, this unit will be the unit that most closely&#xD;
             HLA matches the patient and meets minimum size criteria outlined below of at least 1.5&#xD;
             x 10^7 TNC/kg (i.e. a smaller more closely matched unit will be selected over a larger&#xD;
             less well matched unit as long as minimum criteria are met)&#xD;
&#xD;
          -  DONOR: Unrelated Umbilical Cord Blood: Each UCB unit MUST contain at least 1.5 x 10^7&#xD;
             TNC per kilogram recipient weight&#xD;
&#xD;
          -  DONOR: Unrelated Umbilical Cord Blood: The total cell dose of the combined units must&#xD;
             be at least 3.0 x 10^7 TNC per kilogram recipient weight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with idiopathic aplastic anemia and Fanconi anemia; (patients with aplastic&#xD;
             anemia associated with paroxysmal nocturnal hemoglobinuria [PNH] or inherited marrow&#xD;
             failure syndromes, except Fanconi anemia, will be allowed)&#xD;
&#xD;
          -  Patients with impaired cardiac function as evidenced by ejection fraction &lt; 35% (or,&#xD;
             if unable to obtain ejection fraction, shortening fraction of &lt; 26%) or cardiac&#xD;
             insufficiency requiring treatment or symptomatic coronary artery disease; patients&#xD;
             with a shortening fraction &lt; 26% may be enrolled if approved by a cardiologist&#xD;
&#xD;
          -  Patients with impaired pulmonary function as evidenced by diffusion capacity of the&#xD;
             lung for carbon monoxide (DLCO) &lt; 50% of predicted (or, if unable to perform pulmonary&#xD;
             function tests, then oxygen [O2] saturation &lt; 92% on room air)&#xD;
&#xD;
          -  Patients with impaired renal function as evidenced by creatinine-clearance &lt; 50% for&#xD;
             age, weight, height or serum creatinine &gt; 2 x upper normal limit or dialysis-dependent&#xD;
&#xD;
          -  Patients with evidence of synthetic dysfunction or severe cirrhosis requiring deferral&#xD;
             of conditioning as recommended by a gastroenterology specialist&#xD;
&#xD;
          -  Patients with an active infectious disease requiring deferral of conditioning; as&#xD;
             recommended by an infectious disease specialist&#xD;
&#xD;
          -  Patients who are positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding&#xD;
&#xD;
          -  Patients with a known hypersensitivity to treosulfan and/or fludarabine&#xD;
&#xD;
          -  Receiving another experimental drug within 4 weeks of initiation of conditioning (day&#xD;
             -6) unless approved by the PI&#xD;
&#xD;
          -  DONOR: Deemed unable to undergo marrow harvesting or PBSC mobilization and&#xD;
             leukapheresis&#xD;
&#xD;
          -  DONOR: HIV-positive&#xD;
&#xD;
          -  DONOR: With active infectious hepatitis&#xD;
&#xD;
          -  DONOR: Females with a positive pregnancy test&#xD;
&#xD;
          -  DONOR: HLA-matched sibling cord blood exclusions: Any cord blood units that have not&#xD;
             passed donor screening for infectious disease markers as recommended by the National&#xD;
             Marrow Donor Project (NMDP) will not be used unless a waiver is signed by the clinical&#xD;
             attending allowing use of cord blood unit; cord blood units are presumed to be&#xD;
             cytomegalovirus (CMV) negative regardless of serologic testing due to passive&#xD;
             transmission of maternal CMV antibodies&#xD;
&#xD;
          -  DONOR: Unrelated Umbilical Cord Blood: Any cord blood units with &lt; 1.5 x 10^7 total&#xD;
             nucleated cells per kilogram recipient weight&#xD;
&#xD;
          -  DONOR: Unrelated Umbilical Cord Blood: Any cord blood units that have not passed donor&#xD;
             screening for infectious disease markers as recommended by NMDP will not be used&#xD;
             unless a waiver is signed by the clinical attending allowing use of cord blood unit;&#xD;
             cord blood units are presumed to be CMV negative regardless of serologic testing due&#xD;
             to passive transmission of maternal CMV antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauri M. Burroughs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 11, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <results_first_submitted>June 3, 2021</results_first_submitted>
  <results_first_submitted_qc>July 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2021</results_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Lauri Burroughs</investigator_full_name>
    <investigator_title>Associate Professor, Clinical Research Division, Fred Hutch; Director, Non-Malignant Transplant Program</investigator_title>
  </responsible_party>
  <keyword>nonmalignant diseases</keyword>
  <keyword>nonmalignant inherited disorders</keyword>
  <keyword>primary immunodeficiency diseases</keyword>
  <keyword>primary immune deficiency disorders</keyword>
  <keyword>chronic granulomatous</keyword>
  <keyword>disease</keyword>
  <keyword>IPEX syndrome</keyword>
  <keyword>hemophagocytic lymphohistiocytosis</keyword>
  <keyword>Wiskott Aldrich Syndrome</keyword>
  <keyword>bone marrow failure syndromes</keyword>
  <keyword>Shwachman Diamond Syndrome</keyword>
  <keyword>Dyskeratosis Congenita</keyword>
  <keyword>Diamond Blackfan Anemia</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>metabolic diseases</keyword>
  <keyword>hemoglobinopathies</keyword>
  <keyword>sickle cell disease</keyword>
  <keyword>thalassemia</keyword>
  <keyword>reduced intensity transplantation</keyword>
  <keyword>hematopoietic cell transplantation</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>umbilical cord blood transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT00919503/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Regimen A (PBSCT and BMT)</title>
          <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
        </group>
        <group group_id="P2">
          <title>Regimen B (UBCT)</title>
          <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Regimen A (PBSCT and BMT)</title>
          <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Regimen B (UBCT)</title>
          <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Preliminary Efficacy</title>
        <description>Number of patients engrafted (&gt;5% donor CD3+ peripheral blood chimerisms) at 1 year following transplant</description>
        <time_frame>1 year following transplant</time_frame>
        <population>Regimen B: Three patients expired without CD3+ chimerisms being performed, therefore could not be analyzed for primary efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen A (PBSCT and BMT)</title>
            <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Regimen B (UBCT)</title>
            <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
          </group>
        </group_list>
        <measure>
          <title>Preliminary Efficacy</title>
          <description>Number of patients engrafted (&gt;5% donor CD3+ peripheral blood chimerisms) at 1 year following transplant</description>
          <population>Regimen B: Three patients expired without CD3+ chimerisms being performed, therefore could not be analyzed for primary efficacy</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality</title>
        <description>Number of patients who experienced non-relapse mortality by 1 year following transplant</description>
        <time_frame>1 year following transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regimen A (PBSCT and BMT)</title>
            <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Regimen B (UBCT)</title>
            <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality</title>
          <description>Number of patients who experienced non-relapse mortality by 1 year following transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade II-IV Acute Graft-versus-host Disease</title>
        <description>Number of patients diagnosed with overall grade II-IV acute GVHD by Day 100 post transplant</description>
        <time_frame>Day 100 post transplant</time_frame>
        <population>Regimen B: 2 patients expired too early for evaluation for acute GVHD and could not be evaluated for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen A (PBSCT and BMT)</title>
            <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Regimen B (UBCT)</title>
            <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade II-IV Acute Graft-versus-host Disease</title>
          <description>Number of patients diagnosed with overall grade II-IV acute GVHD by Day 100 post transplant</description>
          <population>Regimen B: 2 patients expired too early for evaluation for acute GVHD and could not be evaluated for this outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With of Chronic Graft-versus-host Disease</title>
        <description>Number of patients diagnosed with chronic GVHD and requiring systemic immunosuppression within 1 year following transplant</description>
        <time_frame>1 year following transplant</time_frame>
        <population>Regimen B: 3 patients expired too early for evaluation for chronic GVHD and could not be evaluated for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen A (PBSCT and BMT)</title>
            <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Regimen B (UBCT)</title>
            <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With of Chronic Graft-versus-host Disease</title>
          <description>Number of patients diagnosed with chronic GVHD and requiring systemic immunosuppression within 1 year following transplant</description>
          <population>Regimen B: 3 patients expired too early for evaluation for chronic GVHD and could not be evaluated for this outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Chimerism CD3 at 100 Days Post Transplant</title>
        <description>Number of patients with peripheral blood donor chimerism for CD3 less than 5%, 5-49%, 50-94% and greater than or equal to 95% at 100 days post transplant.</description>
        <time_frame>Day 100 post transplant</time_frame>
        <population>Regimen B: 3 patients expired without CD3+ chimerisms being performed and could not be evaluated for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen A (PBSCT and BMT)</title>
            <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Regimen B (UBCT)</title>
            <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Chimerism CD3 at 100 Days Post Transplant</title>
          <description>Number of patients with peripheral blood donor chimerism for CD3 less than 5%, 5-49%, 50-94% and greater than or equal to 95% at 100 days post transplant.</description>
          <population>Regimen B: 3 patients expired without CD3+ chimerisms being performed and could not be evaluated for this outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Greater than equal to 95%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 - 94%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-49%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than 5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Response at One Year Following Hematopoietic Cell Transplantation</title>
        <description>Number of patients with no evidence of disease at one year following transplant</description>
        <time_frame>1 year following transplant</time_frame>
        <population>Regimen B: 3 patients expired prior to disease response being evaluated and could not be evaluated for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen A (PBSCT and BMT)</title>
            <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Regimen B (UBCT)</title>
            <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Response at One Year Following Hematopoietic Cell Transplantation</title>
          <description>Number of patients with no evidence of disease at one year following transplant</description>
          <population>Regimen B: 3 patients expired prior to disease response being evaluated and could not be evaluated for this outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution Following Hematopoietic Cell Transplantation</title>
        <description>Number of patients with immune reconstitution (defined by a normal range CD3) at 1 year post transplant</description>
        <time_frame>1 year following transplant</time_frame>
        <population>Regimen A: 11 patients did not have lymphocyte subsets drawn post-transplant and could not be evaluated for outcome; Regimen B: 3 patients expired prior to lymphocyte subsets being evaluated and 2 patients did not have lymphocyte subsets drawn post-transplant and could not be evaluated for outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen A (PBSCT and BMT)</title>
            <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Regimen B (UBCT)</title>
            <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution Following Hematopoietic Cell Transplantation</title>
          <description>Number of patients with immune reconstitution (defined by a normal range CD3) at 1 year post transplant</description>
          <population>Regimen A: 11 patients did not have lymphocyte subsets drawn post-transplant and could not be evaluated for outcome; Regimen B: 3 patients expired prior to lymphocyte subsets being evaluated and 2 patients did not have lymphocyte subsets drawn post-transplant and could not be evaluated for outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infections</title>
        <description>Number of participants with clinically significant infections (bacterial, fungal, viral) requiring treatment within 100 days following transplant</description>
        <time_frame>100 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regimen A (PBSCT and BMT)</title>
            <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Regimen B (UBCT)</title>
            <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infections</title>
          <description>Number of participants with clinically significant infections (bacterial, fungal, viral) requiring treatment within 100 days following transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Number of patients alive at 1 year following transplant</description>
        <time_frame>1 year following transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regimen A (PBSCT and BMT)</title>
            <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Regimen B (UBCT)</title>
            <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of patients alive at 1 year following transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Chimerism CD33 at Day 100 Post Transplant</title>
        <description>Number of patients with peripheral blood donor chimerism for CD33 less than 5%, 5-49%, 50-94% and greater than or equal to 95% at 100 days post transplant.</description>
        <time_frame>100 days post transplant</time_frame>
        <population>Regimen B: 2 patients expired without CD33+ chimerisms being performed and could not be evaluated for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen A (PBSCT and BMT)</title>
            <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Regimen B (UBCT)</title>
            <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Chimerism CD33 at Day 100 Post Transplant</title>
          <description>Number of patients with peripheral blood donor chimerism for CD33 less than 5%, 5-49%, 50-94% and greater than or equal to 95% at 100 days post transplant.</description>
          <population>Regimen B: 2 patients expired without CD33+ chimerisms being performed and could not be evaluated for this outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Greater than equal to 95%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-94%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-49%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than 5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 100 post initiation of conditioning therapy</time_frame>
      <desc>Adverse Events were collected 100 days post initiation of conditioning therapy. All-Cause Mortality was assessed through 10.6 years post transplant (through study completion date 6/10/2020).</desc>
      <group_list>
        <group group_id="E1">
          <title>Regimen A (PBSCT and BMT)</title>
          <description>CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
Allogeneic Bone Marrow Transplantation: Infused IV&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Methotrexate: Given IV&#xD;
Peripheral Blood Stem Cell Transplantation: Infused IV&#xD;
Tacrolimus: Given IV or PO&#xD;
Treosulfan: Given IV</description>
        </group>
        <group group_id="E2">
          <title>Regimen B (UBCT)</title>
          <description>CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .&#xD;
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.&#xD;
Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.&#xD;
Anti-Thymocyte Globulin: Given IV&#xD;
Cyclosporine: Given IV or PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total body irradiation&#xD;
Treosulfan: Given IV&#xD;
Umbilical Cord Blood Transplantation: Single or double unit umbilical cord blood transplant, infused IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia: attributed to rATG</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia: with life- threatening sepsis</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Asystole following central venous catheter placement</sub_title>
                <description>grade 5</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Other: Pneumatosis</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea (associated with GVHD): &gt;15ml/kg per day with abdominal pain</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (not neutropenic): attributed to rATG</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fever (not neutropenic)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis reaction (rATG)</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis with multiorgan failure</sub_title>
                <description>grade 5</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infections and infestations -Other, specify: parainfluenza or sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infections and infestations -Other, specify: CMV meningitis/encephalo</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infections and infestations -Other, specify: Clostridium septicum sepsis</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury (reversible, requiring CRRT/dialysis)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Apnea: Requiring intubation following BAL; attributed to underlying infection</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome (ARDS)</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoxia: Decreased O2 sat requiring support</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension: requiring intervention</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypotension: shock, pressors</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic microangiopathy (requiring intervention) with acute renal fail: Hemolytic uremic syndrome</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="84"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hemolysis (AIHA): Requiring transfusion and sterioids</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy (not requiring intervention)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia: attributed to rATG</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion: Tamponade</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest: Requiring intubation</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid retention - evidence of ascites</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea (associated with GVHD): &gt;15ml/kg per day</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders -Other, specify: pneumatosis</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oral mucositis: Requiring intervention</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Esophageal ulcers: Presumed viral esophagitis</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Colitis: Abdominal pain</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage: Bleeding (requiring transfusion)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (not neutropenic): attributed to rATG</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fever (not neutropenic)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis reaction: Possible reaction to rATG</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations -Other, specify: life-threatening disseminated Adenovirus</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>nfections and infestations -Other, specify: MSSA septic shock</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infections and infestations -Other, specify: Strep viridans, enterococcus bacteremia</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated bilirubin (&gt;3-10x ULN)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusing capacity decreased (DLCO)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Reversible posterior leukoencephalopathy syndrome (PRES)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Seizure (conciousness altered)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Acute kidney injury (reversible, requiring CRRT/dialysis)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional urerine (menstrual) bleeding: requiring transfusion</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>sleep apnea: Obstructive</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoxia: decreased O2 sat</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoxia: requiring intubation</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome (ARDS)</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash (&gt;50%)</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension: requiring intervention</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lauri Burroughs</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-2396</phone>
      <email>lburroug@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

